BR0309337A - Monoterapia para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox2) - Google Patents

Monoterapia para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox2)

Info

Publication number
BR0309337A
BR0309337A BR0309337-9A BR0309337A BR0309337A BR 0309337 A BR0309337 A BR 0309337A BR 0309337 A BR0309337 A BR 0309337A BR 0309337 A BR0309337 A BR 0309337A
Authority
BR
Brazil
Prior art keywords
inhibitors
disease
parkinson
treatment
cyclooxygenase
Prior art date
Application number
BR0309337-9A
Other languages
English (en)
Inventor
Diane T Stephenson
Peter C Isakson
Timothy J Maziasz
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0309337A publication Critical patent/BR0309337A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

"MONOTERAPIA PARA O TRATAMENTO DE DOENçA DE PARKINSON COM INIBIDORES DE CICLOOXIGENASE-2 (COX 2)". A invenção refere-se a um método de tratamento, prevenção ou inibição de doença de Parkinson, em um indivíduo que necessite de tal tratamento, inibição ou prevenção. O método compreende tratar o indivíduo com um ou mais inibidores seletivos de ciclooxigenase-2, seus ésteres, sais ou pró-medicamentos, onde a quantidade de um ou mais inibidores seletivos de ciclooxigenase-2, ésteres, sais, ou pró-medicamentos dos mesmos, constitui uma quantidade eficaz do inibidor ou inibidores de COX 2 para o tratamento, inibição ou prevenção de doença de Parkinson.
BR0309337-9A 2002-04-18 2003-04-14 Monoterapia para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox2) BR0309337A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37331702P 2002-04-18 2002-04-18
PCT/US2003/011517 WO2003088959A2 (en) 2002-04-18 2003-04-14 Treatment of parkinson's disease with cyclooxygenase-2 (cox 2) inhibitor(s)

Publications (1)

Publication Number Publication Date
BR0309337A true BR0309337A (pt) 2005-02-15

Family

ID=29251014

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309337-9A BR0309337A (pt) 2002-04-18 2003-04-14 Monoterapia para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox2)

Country Status (8)

Country Link
US (1) US20040006100A1 (pt)
EP (1) EP1505962A2 (pt)
JP (1) JP2005532293A (pt)
AU (1) AU2003226379A1 (pt)
BR (1) BR0309337A (pt)
CA (1) CA2482510A1 (pt)
MX (1) MXPA04010186A (pt)
WO (1) WO2003088959A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005018564A2 (en) * 2003-08-22 2005-03-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476944A (en) * 1991-11-18 1995-12-19 G. D. Searle & Co. Derivatives of cyclic phenolic thioethers
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
RO118291B1 (ro) * 1993-11-30 2003-04-30 Searle & Co Derivati de pirazol 1,3,4,5 - tetrasubstituiti si compozitie farmaceutica care ii contine
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
IS4233A (is) * 1993-12-22 1995-06-23 Astra Aktiebolag Misleit hringtengd efnasambönd
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
GB9514518D0 (en) * 1995-07-15 1995-09-13 Sod Conseils Rech Applic Guanidine salt inhibitors of NO synthase and cyclooxygenase
US6180651B1 (en) * 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
ES2311571T3 (es) * 1996-04-12 2009-02-16 G.D. Searle Llc Derivados de bencenosulfonamida sustituidos como profarmacos de inhibidores de cox-2.
SK167798A3 (en) * 1996-06-07 2000-02-14 Procter & Gamble Dihydrobenzopyran and related compounds useful as anti-inflammatory agents
US6005000A (en) * 1996-08-22 1999-12-21 Oxis International, Inc. 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
SE9701304D0 (sv) * 1997-04-09 1997-04-09 Astra Pharma Prod Compounds
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
JP2002517486A (ja) * 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
US6277878B1 (en) * 1998-09-07 2001-08-21 Pfizer Inc Substituted indole compounds as anti-inflammatory and analgesic agents
AU764875B2 (en) * 1998-11-12 2003-09-04 Merck & Co., Inc. Combination of a GABA-A alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin
MXPA00006605A (es) * 1999-07-02 2004-12-09 Pfizer Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
ATE245639T1 (de) * 1999-12-03 2003-08-15 Pfizer Prod Inc Acetylenderivate zur verwendung als schmerzstillendes oder entzündungshemmendes mittel
US6306842B1 (en) * 2000-06-02 2001-10-23 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor
GB0019006D0 (en) * 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
AU2002306868A1 (en) * 2001-03-28 2002-10-15 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
US7091343B2 (en) * 2002-03-15 2006-08-15 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2003225800A1 (en) * 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases

Also Published As

Publication number Publication date
EP1505962A2 (en) 2005-02-16
WO2003088959A3 (en) 2003-12-31
JP2005532293A (ja) 2005-10-27
AU2003226379A1 (en) 2003-11-03
MXPA04010186A (es) 2005-02-03
AU2003226379A8 (en) 2003-11-03
CA2482510A1 (en) 2003-10-30
WO2003088959A2 (en) 2003-10-30
US20040006100A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
BR0309259A (pt) Terapia combinada para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox 2)
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
CY1125274T1 (el) Μεθοδοι για την θεραπεια συνθηκων που σχετιζονται με την ενεργοποιηση συμπληρωματικου εξαρτωμενου απο την masp-2
BR0317183A (pt) Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno
NI200700320A (es) Inhibidores de la actividad akt
CY1109295T1 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
CY1125022T1 (el) Μεθοδοι για θεραπεια καταστασεων που συνδυαζονται με εξαρτωμενη απο masp-2 ενεργοποιηση συμπληρωματος
BR9916785A (pt) Tratamento de asma com inibidores mek
ATE461923T1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
ATE536349T1 (de) In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
TW200716183A (en) Parakeratosis inhibitor, pore-contracting agent and external composition for skin
ECSP099376A (es) Inhibidores de la actividad de la akt
PL402389A1 (pl) Sposób hamowania aktywnosci kinazy Raf u ludzi lub zwierzat
BRPI0617165B1 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
DK1297851T3 (da) Inhibering af histondeacetylasesom behandling af hjertehypertrofi
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos
BR9912501A (pt) Tratamento de distúrbios hiperproliferativos
TW200616621A (en) Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals
BR0316238A (pt) Quimioterapia de associação compreendendo um inibidor de mek e capecitabina para tratamento de câncer
CR20230564A (es) Compuestos indol sustituidos y métodos de uso de los mismos
PA8583501A1 (es) Derivados de pirrolidona como inhibidores de maob
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A,5A,6A,7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.